|
Market Closed -
Nasdaq
00:00:01 07/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 19.74 USD | -1.84% |
|
-2.37% | -26.10% |
| 09-29 | Neuren Says US Patent Allowance Could Extend Trofinetide Protection to 2041 | MT |
| 09-29 | Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent | MT |
Company Valuation: Acadia Pharmaceuticals Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,752 | 2,578 | 5,140 | 3,053 | 4,519 | 3,401 | - | - |
| Change | - | -31.29% | 99.4% | -40.6% | 48% | -24.73% | - | - |
| Enterprise Value (EV) 1 | 3,231 | 2,161 | 4,702 | 2,297 | 3,699 | 2,392 | 2,164 | 1,670 |
| Change | - | -33.12% | 117.56% | -51.14% | 61.02% | -35.33% | -9.54% | -22.84% |
| P/E | -22.2x | -11.9x | -84.6x | 13.5x | 11.6x | 32.3x | 22.9x | 13.1x |
| PBR | 6.95x | 6.44x | 11.9x | 4.17x | 3.66x | 2.51x | 2.17x | 1.82x |
| PEG | - | -0.4x | 1.2x | -0x | 0.2x | -0.4x | 0.6x | 0.2x |
| Capitalization / Revenue | 7.75x | 4.98x | 7.08x | 3.19x | 4.22x | 2.67x | 2.37x | 2.12x |
| EV / Revenue | 6.67x | 4.18x | 6.47x | 2.4x | 3.45x | 1.88x | 1.51x | 1.04x |
| EV / EBITDA | -19.3x | -9.75x | -69.3x | 9.31x | 31.7x | 21x | 10.9x | 4.84x |
| EV / EBIT | -19x | -9.67x | -64.1x | 9.95x | 35.3x | 22.1x | 12.5x | 5.3x |
| EV / FCF | -25.5x | -19x | 282x | 14.6x | 35.2x | 10.3x | 22.5x | 5.2x |
| FCF Yield | -3.92% | -5.28% | 0.35% | 6.84% | 2.84% | 9.74% | 4.45% | 19.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.05 | -1.34 | -0.37 | 1.36 | 2.3 | 0.6106 | 0.8632 | 1.506 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 484.1 | 517.2 | 726.4 | 957.8 | 1,072 | 1,273 | 1,433 | 1,604 |
| EBITDA 1 | -167.1 | -221.6 | -67.83 | 246.7 | 116.6 | 114 | 198.2 | 345.2 |
| EBIT 1 | -170.4 | -223.6 | -73.38 | 230.8 | 104.8 | 108.4 | 173.2 | 315.2 |
| Net income 1 | -167.9 | -216 | -61.29 | 226.5 | 391 | 106.6 | 157.4 | 281.7 |
| Net Debt 1 | -520.7 | -416.8 | -438.9 | -756 | -819.7 | -1,009 | -1,237 | -1,731 |
| Reference price 2 | 23.34 | 15.92 | 31.31 | 18.35 | 26.71 | 19.74 | 19.74 | 19.74 |
| Nbr of stocks (in thousands) | 160,756 | 161,931 | 164,180 | 166,392 | 169,182 | 172,306 | - | - |
| Announcement Date | 28/02/22 | 27/02/23 | 27/02/24 | 26/02/25 | 25/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.33x | 1.88x | 20.99x | -.--% | 3.4B | |
| 21.73x | 7.77x | 15.6x | 1.37% | 74.69B | |
| 30.56x | 8.79x | 27.4x | 0.04% | 58.81B | |
| 33.6x | 6.04x | 18.08x | 0.96% | 48.45B | |
| -20.7x | 214.73x | -22.18x | -.--% | 42.84B | |
| 33.49x | 3.25x | 14.04x | -.--% | 42.79B | |
| 48.17x | 5.48x | 30.1x | -.--% | 41.25B | |
| 27.6x | 7.84x | 20.39x | 0.41% | 31.13B | |
| 35.01x | 7.5x | 19.48x | -.--% | 30.28B | |
| -14.91x | 5.52x | -6.94x | -.--% | 24.05B | |
| Average | 22.69x | 26.88x | 13.70x | 0.28% | 39.77B | |
| Weighted average by Cap. | 23.27x | 29.08x | 14.27x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ACAD Stock
- Valuation Acadia Pharmaceuticals Inc.
Select your edition
All financial news and data tailored to specific country editions
